Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
NVCR Stock Chart & Stats
$12.84
-$0.69(-2.38%)
At close: 4:00 PM EST
$12.84
-$0.69(-2.38%)
Day’s Range― - ―
52-Week Range$10.70 - $32.06
Previous CloseN/A
Volume205.01K
Average Volume (3M)1.84M
Market Cap
$1.44B
Enterprise Value$1.21B
Total Cash (Recent Filing)$1.04B
Total Debt (Recent Filing)$797.94M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Feb 19, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding111,981,980
10 Day Avg. Volume1,867,265
30 Day Avg. Volume1,840,236
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)8.92
Price to Sales (P/S)5.31
P/FCF Ratio-46.42
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit2.49
Enterprise Value/Ebitda-11.24
Forecast
1Y Price Target
$24.30Price Target Upside89.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.4
Revenue Forecast (FY)$649.94M
Bulls Say, Bears Say
Bulls Say
Leadership TransitionThe planned CEO transition with Frank Leonard as the new CEO is seen as a strategic move ahead of multiple new launches and international expansion for TTFields.
Market ExpansionApproval in Japan is expected to be a strong region for NSCLC revenues, given the high prevalence of NSCLC and appreciation for medical devices.
Regulatory ApprovalsExpected FDA approvals for TTFields in locally advanced pancreatic cancer and brain metastases from NSCLC are anticipated to be key growth drivers.
Bears Say
Launch PerformanceThe launch of TTFields in NSCLC has trended slower than expected, which is a concern for the company's performance.
Revenue GrowthThe ramp in lung revenues is significantly slower than initial expectations, due to the severe patient population and unfamiliarity with device-based therapies.
NovoCure News
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $10.70 and its highest was $32.05 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is $1.44B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Feb 19, 2026 which is in 59 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Oct 30, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.42 by $0.09.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -0.4.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 111,981,980 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.42. Following the earnings report the stock price went down -4.896%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Currently, no hedge funds are holding shares in NVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.30 (89.25% Upside)
$24.30 (89.25% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 83%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 760.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.76%
12-Months-Change
Fundamentals
Return on Equity
-50.60%
Trailing 12-Months
Asset Growth
11.39%
Trailing 12-Months
Company Description
NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NVCR Company Deck
NVCR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights strong growth in the GBM segment and international markets, along with regulatory progress for new indications. However, these positives are tempered by challenges in the non-small cell lung cancer launch, flat growth in the U.S. market, and financial setbacks such as reduced gross margin and net loss.View all NVCR earnings summariesNVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$24.30
▲(89.25% Upside)
Technical Analysis
Ownership Overview
2.19% Insiders
24.96% Mutual Funds
19.06% Other Institutional Investors
37.66% Public Companies and Individual Investors